Article Text

other Versions

PDF
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
  1. Mirjam B Zeisel1,2,
  2. Julie Lucifora3,
  3. William S Mason4,
  4. Camille Sureau5,
  5. Jürgen Beck6,
  6. Massimo Levrero7,8,
  7. Michael Kann9,10,11,
  8. Percy A Knolle12,
  9. Monsef Benkirane13,
  10. David Durantel3,
  11. Marie-Louise Michel14,
  12. Brigitte Autran15,16,17,
  13. François-Loïc Cosset18,19,
  14. Hélène Strick-Marchand20,
  15. Christian Trépo3,21,
  16. Jia-Horng Kao22,
  17. Fabrice Carrat23,24,25,
  18. Karine Lacombe23,24,25,
  19. Raymond F Schinazi26,
  20. Françoise Barré-Sinoussi27,
  21. Jean-François Delfraissy28,
  22. Fabien Zoulim3,21
  1. 1Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
  2. 2Université de Strasbourg, Strasbourg, France
  3. 3Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL), Lyon, France
  4. 4Fox Chase Cancer Center, Philadelphia, USA
  5. 5INTS, Laboratoire de Virologie Moléculaire, Paris, France
  6. 6Department of Internal Medicine 2/Molecular Biology, University Hospital Freiburg, Freiburg, Germany
  7. 7Center for Life Nanosciences (CNLS)—IIT/Sapienza, Rome, Italy
  8. 8Laboratory of Gene Expression, Department of Internal Medicine (DMISM), Sapienza University of Rome, Italy
  9. 9Université de Bordeaux, Microbiologie fondamentale et Pathogénicité, UMR 5234, Bordeaux, France
  10. 10CNRS, Microbiologie fondamentale et Pathogénicité, UMR 5234, Bordeaux, France
  11. 11CHU de Bordeaux, Bordeaux, France
  12. 12Technische Universität München, Institut für Molekulare Immunologie, München, Germany
  13. 13Institut de Génétique Humaine, Laboratoire de Virologie Moléculaire, CNRS UPR1142, Montpellier, France
  14. 14Laboratoire de Pathogenèse des Virus de l'Hépatite B, Département de Virologie, Institut Pasteur, Paris, France
  15. 15Laboratory of Immunity and Infection, Inserm U945, Paris, France
  16. 16Laboratory of Immunity and Infection, UPMC University Paris 06, Unité mixte de recherche-S945, Paris, France
  17. 17Inserm, IFR 113, Immunité-Cancer-Infection, Paris, France
  18. 18CIRI—International Center for Infectiology Research, Team EVIR, Université de Lyon, Lyon, France. Inserm, U1111, Lyon, France Ecole Normale Supérieure de Lyon, Lyon, France. CNRS, UMR5308, Lyon, France
  19. 19LabEx Ecofect, Université de Lyon, Lyon, France
  20. 20Innate Immunity Unit, Institut Pasteur, Inserm U668, Paris, France
  21. 21Department of Hepatology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France
  22. 22Department of Internal Medicine, Department of Medical Research, Graduate Institute of Clinical Medicine, and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
  23. 23Inserm, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
  24. 24Sorbonne Universités, UPMC Univ Paris 06, Paris, France
  25. 25Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France
  26. 26Center for AIDS Research, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia, USA
  27. 27Inserm and Unit of Regulation of Retroviral Infections, Department of Virology, Institut Pasteur, Paris, France
  28. 28ANRS (France Recherche Nord & Sud Sida-HIV Hépatites), Paris, France
  1. Correspondence to Professor Fabien Zoulim, Lyon University, INSERM U1052—CRCL, Hospices Civils de Lyon 69003, France; fabien.zoulim{at}inserm.fr

Abstract

HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis ‘HBV Cure’ programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.

  • HEPATITIS B

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.